Stock Watch: Pharma And Anti-Pharma
How Merck And Pfizer Polarized Second-Quarter Earnings
Executive Summary
While not direct competitors in all therapeutic areas, Pfizer’s and Merck’s sales offered some stark contrasts in the second quarter.
You may also be interested in...
Stock Watch: Back To Pharma Basics
The pandemic distorted much in drug and diagnostic companies’ quarterly financial reports, but that time is over and investors now applaud organic revenue growth.
Pfizer Cost Improvement Program Depends On COVID Outlook
If COVID-19 product sales don’t meet assumptions this fall, the company said it will consider a cost reduction program to better align costs with future revenue projections.
Stock Watch: Johnson & Johnson’s Q2 Helps Pharma Sentiment
Pharmaceutical stocks have underperformed in the year to date, but J&J, Novartis and GSK may have started to turn the worm.